DAE HWA Pharmaceutical Co. Ltd (067080) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of DAE HWA Pharmaceutical Co. Ltd KRW 1,846, price KRW 11,450, upside -83.9%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Weakest SetupStrongly overvalued and low quality.
!Fair value 1,846 KRW · Strongly overvalued (−84%)
!Quality 45/100
!Mixed Growth(revenue 5y +5.5 %/yr)
!Thin margins · 1.3% net margin (TTM)
✓Low debt · generates free cash flow
·1.31% dividend yield
!Trails peers(2/10)
!Narrow moat23/100
!Evidence only low, so the estimate is less certain
Watch DAE HWA Pharmaceutical Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 5,630 KRW – 23,032 KRW · fair‑value band 1,178 KRW – 2,445 KRW · the 11,450 KRW price screens above the 1,846 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow DAE HWA Pharmaceutical Co. in your weekly email
Every Wednesday you see whether DAE HWA Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea.
Show more
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthritis, gastro-intestinal, obesity, antispasmodic, diabetics, hypertension, hyperlipemia, antithrombotic and anticoagulant, hepatic, erectile dysfunction, urinary incontinence, prostatic hyperplasia, pregnancy, bug bite, anthelmintics, and cosmetic care, as well as vitamins and minerals, tonics, nutrition products. It also provides transdermal drug delivery system, a pharmaceutical preparation that is applied to the intact skin for systemic absorption; and active pharmaceutical ingredients. The company also exports its products to approximately 22 countries, including Asia, South America, the Middle East, and Africa. DAE HWA Pharmaceutical Co., Ltd. was founded in 1984 and is headquartered in Seoul, South Korea.
Stock analysis
DAE HWA Pharmaceutical Co. Ltd (067080) currently trades at 11,450 KRW, while our model-based Fair Value estimate is 1,846 KRW, implying the stock looks roughly 520.3% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 2,772 KRW per share, and 0 of the 21 models we run sit above the 11,450 KRW price.
Bear case: the Earnings-Based group reads lowest at 576.24 KRW, and 21 of the 21 models stay below the price. Evidence for this calculation is low.
Scenario range: 1,178 KRW (bear) to 2,445 KRW (bull), the price of 11,450 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
DAE HWA Pharmaceutical Co. Ltd reported revenue of 143B KRW in FY2025 versus 117B KRW in FY2021, a compound +5.1%/yr. Reported net income was 1.7B KRW in FY2025, compounding −7.1%/yr from FY2021.
Key figures
Market cap 201B KRW (≈ $147M) · P/S ratio 1.14 · Dividend yield 1.3% · Net margin 1.2% · Return on equity 3.0% · Return on assets (EBIT) 1.5% · Operating margin 1.2% · Revenue (TTM) 143B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 50% below its 52-week high and 45% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −84%, 067080 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (576.24 KRW to 7,244 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 1,178 KRWFair Value 1,846 KRWBull 2,445 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Start year 2020 (pandemic). Over 10 years: +0.3% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +3.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.3%
Dividend (yield on the price)1.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−24% vs −8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 2%
Start year 2020 (pandemic)
⚠ Rate on operating basis: 2025 sits 101% above its own trend.
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
Compare DAE HWA Pharmaceutical Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside−84% · Bottom 25%
Profitability
Return on equity (TTM)3% · Below median
Return on assets1% · Below median
Net margin (TTM)1% · Below median
Operating margin (TTM)1% · Below median
Growth and dividend
Revenue growth1% · Below median
Dividend yield (TTM)1.3% · Below median
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/FCF0.2× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)5· sector 20
PAST (return on equity)12· sector 27
HEALTH (low debt)98· sector 96
DIVIDEND (yield)26· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DAE HWA Pharmaceutical Co. Ltd (067080) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,846 KRW versus a price of 11,450 KRW, about −84% upside (overvalued).
What is the fair value of 067080?
Our model-based fair value for DAE HWA Pharmaceutical Co. Ltd is 1,846 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 11,450 KRW.
What is the quality score of 067080?
DAE HWA Pharmaceutical Co. Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DAE HWA Pharmaceutical Co. Ltd (067080)?
Our model-based price target is the fair value of 1,846 KRW (as of Sep 24, 2026) from 21 valuation models. Cautious scenario 1,178 KRW, optimistic scenario 2,445 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the DAE HWA Pharmaceutical Co. Ltd stock forecast for 2026?
Our models put fair value at 1,846 KRW, about −84% upside versus a price of 11,450 KRW (overvalued). Cautious scenario 1,178 KRW, optimistic scenario 2,445 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of DAE HWA Pharmaceutical Co. Ltd (067080)?
DAE HWA Pharmaceutical Co. Ltd reported trailing-twelve-month revenue of about 143B KRW (latest available figure, as of Sep 24, 2026).
Does DAE HWA Pharmaceutical Co. Ltd pay a dividend?
DAE HWA Pharmaceutical Co. Ltd currently shows a dividend yield of about 1.31% relative to its recent price (as of Sep 24, 2026).
What growth is priced into DAE HWA Pharmaceutical Co. Ltd (067080)?
For today's price to be fair in a discounted-cash-flow model, DAE HWA Pharmaceutical Co. Ltd would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 067080 use?
Our models discount DAE HWA Pharmaceutical Co. Ltd at 13.1 %: a base by market capitalisation (micro), country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DAE HWA Pharmaceutical Co. Ltd that is more than 80 % per year a year over ten years, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has DAE HWA Pharmaceutical Co. Ltd (067080) delivered so far?
Over the past 5 years revenue at DAE HWA Pharmaceutical Co. Ltd grew +5.5 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DAE HWA Pharmaceutical Co. Ltd (067080) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into DAE HWA Pharmaceutical Co. Ltd (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DAE HWA Pharmaceutical Co. Ltd (067080)?
The free-cash-flow yield on the price is 0.35 %: that much free cash flow DAE HWA Pharmaceutical Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DAE HWA Pharmaceutical Co. Ltd (067080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DAE HWA Pharmaceutical Co. Ltd it is 1,846 KRW per share (as of Sep 24, 2026), against a price of 11,450 KRW. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is DAE HWA Pharmaceutical Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 067080 trades above its calculated fair value: price 11,450 KRW, fair value 1,846 KRW, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 067080?
No. The price is what the market pays today (11,450 KRW); the fair value is what the company's own numbers justify (1,846 KRW). For DAE HWA Pharmaceutical Co. Ltd the two are 9,604 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is DAE HWA Pharmaceutical Co. Ltd worth?
The market values DAE HWA Pharmaceutical Co. Ltd at about 201B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 11,450 KRW; our models calculate a fair value of 1,846 KRW per share.
What do the bullish and bearish scenarios say about 067080?
Our models span a range for DAE HWA Pharmaceutical Co. Ltd: cautious scenario 1,178 KRW, base 1,846 KRW, optimistic 2,445 KRW per share (as of Sep 24, 2026, price 11,450 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DAE HWA Pharmaceutical Co. Ltd (067080)?
Balance-sheet figures for DAE HWA Pharmaceutical Co. Ltd (as of Sep 24, 2026): return on equity 3.0%, debt of 0.05 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 067080 from its 52-week high?
DAE HWA Pharmaceutical Co. Ltd trades at 11,450 KRW, about 50% below its 52-week high of 23,032 KRW and 45% above the low of 7,870 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,846 KRW is for.
Which stocks are comparable to DAE HWA Pharmaceutical Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DAE HWA Pharmaceutical Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 11,450 KRW, calculated fair value 1,846 KRW (−84%), Quality Score 45/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 067080 calculated?
We run DAE HWA Pharmaceutical Co. Ltd through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,846 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. DAE HWA Pharmaceutical Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DAE HWA Pharmaceutical Co. Ltd (067080)?
The closing price on Sep 23, 2026 was 11,450 KRW. Our model-based fair value is 1,846 KRW, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DAE HWA Pharmaceutical Co. Ltd right now?
The price sits above even our optimistic bull case (2,445 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (1,178 KRW to 2,445 KRW) leaves room in how you read the outcome.
Key figures of DAE HWA Pharmaceutical Co. Ltd
How large is the market capitalisation of DAE HWA Pharmaceutical Co. Ltd (067080)?
The market capitalisation of DAE HWA Pharmaceutical Co. Ltd is 201B KRW (≈ $147M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DAE HWA Pharmaceutical Co. Ltd (067080)?
The price-to-sales ratio of DAE HWA Pharmaceutical Co. Ltd is 1.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of DAE HWA Pharmaceutical Co. Ltd (067080)?
The dividend yield of DAE HWA Pharmaceutical Co. Ltd is 1.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DAE HWA Pharmaceutical Co. Ltd (067080)?
The net margin of DAE HWA Pharmaceutical Co. Ltd is 1.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DAE HWA Pharmaceutical Co. Ltd (067080)?
The return on equity (ROE) of DAE HWA Pharmaceutical Co. Ltd is 3.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DAE HWA Pharmaceutical Co. Ltd (067080)?
On an EBIT basis the return on assets of DAE HWA Pharmaceutical Co. Ltd is 1.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DAE HWA Pharmaceutical Co. Ltd (067080)?
The operating margin of DAE HWA Pharmaceutical Co. Ltd is 1.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DAE HWA Pharmaceutical Co. Ltd (067080)?
Revenue at DAE HWA Pharmaceutical Co. Ltd is growing +1.0% versus a year earlier (3y avg +2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DAE HWA Pharmaceutical Co. Ltd (067080)?
Earnings per share at DAE HWA Pharmaceutical Co. Ltd are growing +112% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does DAE HWA Pharmaceutical Co. Ltd (067080) carry?
The net debt of DAE HWA Pharmaceutical Co. Ltd is 95.2B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DAE HWA Pharmaceutical Co. Ltd in the live analysis
One click puts DAE HWA Pharmaceutical Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
